IceCure Medical (NASDAQ:ICCM) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of IceCure Medical (NASDAQ:ICCM) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

A number of other research analysts have also issued reports on the stock. Zacks Research lowered shares of IceCure Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, August 14th. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $52.50.

IceCure Medical Price Performance

Shares of NASDAQ ICCM opened at $1.95 on Friday. The firm has a market cap of $6.69 million, a price-to-earnings ratio of -0.23 and a beta of 0.45. The stock’s fifty day moving average price is $2.70 and its two-hundred day moving average price is $6.87. IceCure Medical has a one year low of $1.95 and a one year high of $42.00.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%.The firm had revenue of $0.91 million for the quarter. On average, equities analysts anticipate that IceCure Medical will post -4.61 earnings per share for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd. is an Israel-based medical device company that develops minimally invasive cryoablation technology for the treatment of tumors. The company’s technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to more invasive surgical procedures.

Its primary product, the ProSense system, is designed to deliver controlled cryoablation through a thin probe inserted into a tumor under image guidance. The system has been developed for use in a range of tumor types, including breast, kidney, liver, lung and bone tumors, and has received regulatory clearances and approvals for certain indications in markets including the United States and other countries.

IceCure Medical is headquartered in Caesarea, Israel, and serves healthcare providers through commercial and distribution activities in international markets, including North America, Europe and Asia.